1 article
-
The Renaissance and Resilience of CB1 Reverse Agonists: From Central Liabilities to Peripheral Promise
Abstract: Building upon these foundational insights, current research has increasingly focused on refining the pharmacological profile of CB1 reverse agonists to maximize therapeutic benefit while minimizing central adverse effects. The adverse neuropsychiatric outcomes associated with first-generation agents such as Rimonabant including anxiety, depression, and suicidal ideation highlighted the critical role of central CB1 receptors in mood regulation. Consequently, drug development strategies have shifted toward peripherally restricted CB1 reverse agonists that exhibit …
Published in International Journal of Cheminformatics · Vol. 4, Issue 1, 2026 · pp. 30–35 Read article